Developments in endocrine therapy for breast cancer

Akira Matsui, Tadashi Ikeda, Hiromitsu Jinno, Gengo Tajima, Takashi Hohjou, Hideyuki Tokura, Yoko Mitsui, Souta Asaga, Takeshi Muto, Masaki Kitajima

Research output: Contribution to journalArticle

Abstract

After the usefulness of ovariectomy in breast cancer patients was demonstrated, endocrine therapy has been one of the most effective treatments of breast cancer. Thereafter, it became clear that estrogen receptors (ERs) existed in the cells of breast cancer. After it was found that ERs could be used as a predictive factor of endocrine therapy for breast cancer, the validity of endocrine therapy has became more certain. Tamoxifen, a major selective estrogen receptor modulator, is the first agent which has shown evidence of improving survival time and disease-free survival time in the treatment of breast cancer, and is the standard treatment, widely used in the treatment of breast cancer all over the world. LH-RH analogue, commonly used in ablation treatment among premenopausal women, produces the same effect as ovariectomy, and recently has shown good results equivalent to chemotherapy in premenopausal breast cancer treatment. Furthermore, aromatase inhibitors as a form of ablation treatment of postmenopausal women have been used recently. In comparison with tamoxifen, aromatase inhibitors have revealed the same or more effective result in postmenopausal breast cancer treatment. In the near future, endocrine mechanisms in the body and the molecular mechanisms of transcription by ER will be more clearly elucidated, and then new kinds of agent and combined therapies for the endocrine treatment of breast cancer will be developed. Currently, many clinical randomized trials are being conducted to examine the effectiveness of new endocrine treatment. Significant changes are occurring in the endocrine treatment of breast cancer.

Original languageEnglish
Pages (from-to)1138-1145
Number of pages8
JournalJapanese Journal of Cancer and Chemotherapy
Volume29
Issue number7
Publication statusPublished - 2002 Jul

Fingerprint

Breast Neoplasms
Therapeutics
Estrogen Receptors
Aromatase Inhibitors
Ovariectomy
Tamoxifen
Selective Estrogen Receptor Modulators
Gonadotropin-Releasing Hormone
Disease-Free Survival
Randomized Controlled Trials
Drug Therapy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Matsui, A., Ikeda, T., Jinno, H., Tajima, G., Hohjou, T., Tokura, H., ... Kitajima, M. (2002). Developments in endocrine therapy for breast cancer. Japanese Journal of Cancer and Chemotherapy, 29(7), 1138-1145.

Developments in endocrine therapy for breast cancer. / Matsui, Akira; Ikeda, Tadashi; Jinno, Hiromitsu; Tajima, Gengo; Hohjou, Takashi; Tokura, Hideyuki; Mitsui, Yoko; Asaga, Souta; Muto, Takeshi; Kitajima, Masaki.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 29, No. 7, 07.2002, p. 1138-1145.

Research output: Contribution to journalArticle

Matsui, A, Ikeda, T, Jinno, H, Tajima, G, Hohjou, T, Tokura, H, Mitsui, Y, Asaga, S, Muto, T & Kitajima, M 2002, 'Developments in endocrine therapy for breast cancer', Japanese Journal of Cancer and Chemotherapy, vol. 29, no. 7, pp. 1138-1145.
Matsui A, Ikeda T, Jinno H, Tajima G, Hohjou T, Tokura H et al. Developments in endocrine therapy for breast cancer. Japanese Journal of Cancer and Chemotherapy. 2002 Jul;29(7):1138-1145.
Matsui, Akira ; Ikeda, Tadashi ; Jinno, Hiromitsu ; Tajima, Gengo ; Hohjou, Takashi ; Tokura, Hideyuki ; Mitsui, Yoko ; Asaga, Souta ; Muto, Takeshi ; Kitajima, Masaki. / Developments in endocrine therapy for breast cancer. In: Japanese Journal of Cancer and Chemotherapy. 2002 ; Vol. 29, No. 7. pp. 1138-1145.
@article{6139809714ee408c93ab8f512738e511,
title = "Developments in endocrine therapy for breast cancer",
abstract = "After the usefulness of ovariectomy in breast cancer patients was demonstrated, endocrine therapy has been one of the most effective treatments of breast cancer. Thereafter, it became clear that estrogen receptors (ERs) existed in the cells of breast cancer. After it was found that ERs could be used as a predictive factor of endocrine therapy for breast cancer, the validity of endocrine therapy has became more certain. Tamoxifen, a major selective estrogen receptor modulator, is the first agent which has shown evidence of improving survival time and disease-free survival time in the treatment of breast cancer, and is the standard treatment, widely used in the treatment of breast cancer all over the world. LH-RH analogue, commonly used in ablation treatment among premenopausal women, produces the same effect as ovariectomy, and recently has shown good results equivalent to chemotherapy in premenopausal breast cancer treatment. Furthermore, aromatase inhibitors as a form of ablation treatment of postmenopausal women have been used recently. In comparison with tamoxifen, aromatase inhibitors have revealed the same or more effective result in postmenopausal breast cancer treatment. In the near future, endocrine mechanisms in the body and the molecular mechanisms of transcription by ER will be more clearly elucidated, and then new kinds of agent and combined therapies for the endocrine treatment of breast cancer will be developed. Currently, many clinical randomized trials are being conducted to examine the effectiveness of new endocrine treatment. Significant changes are occurring in the endocrine treatment of breast cancer.",
author = "Akira Matsui and Tadashi Ikeda and Hiromitsu Jinno and Gengo Tajima and Takashi Hohjou and Hideyuki Tokura and Yoko Mitsui and Souta Asaga and Takeshi Muto and Masaki Kitajima",
year = "2002",
month = "7",
language = "English",
volume = "29",
pages = "1138--1145",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "7",

}

TY - JOUR

T1 - Developments in endocrine therapy for breast cancer

AU - Matsui, Akira

AU - Ikeda, Tadashi

AU - Jinno, Hiromitsu

AU - Tajima, Gengo

AU - Hohjou, Takashi

AU - Tokura, Hideyuki

AU - Mitsui, Yoko

AU - Asaga, Souta

AU - Muto, Takeshi

AU - Kitajima, Masaki

PY - 2002/7

Y1 - 2002/7

N2 - After the usefulness of ovariectomy in breast cancer patients was demonstrated, endocrine therapy has been one of the most effective treatments of breast cancer. Thereafter, it became clear that estrogen receptors (ERs) existed in the cells of breast cancer. After it was found that ERs could be used as a predictive factor of endocrine therapy for breast cancer, the validity of endocrine therapy has became more certain. Tamoxifen, a major selective estrogen receptor modulator, is the first agent which has shown evidence of improving survival time and disease-free survival time in the treatment of breast cancer, and is the standard treatment, widely used in the treatment of breast cancer all over the world. LH-RH analogue, commonly used in ablation treatment among premenopausal women, produces the same effect as ovariectomy, and recently has shown good results equivalent to chemotherapy in premenopausal breast cancer treatment. Furthermore, aromatase inhibitors as a form of ablation treatment of postmenopausal women have been used recently. In comparison with tamoxifen, aromatase inhibitors have revealed the same or more effective result in postmenopausal breast cancer treatment. In the near future, endocrine mechanisms in the body and the molecular mechanisms of transcription by ER will be more clearly elucidated, and then new kinds of agent and combined therapies for the endocrine treatment of breast cancer will be developed. Currently, many clinical randomized trials are being conducted to examine the effectiveness of new endocrine treatment. Significant changes are occurring in the endocrine treatment of breast cancer.

AB - After the usefulness of ovariectomy in breast cancer patients was demonstrated, endocrine therapy has been one of the most effective treatments of breast cancer. Thereafter, it became clear that estrogen receptors (ERs) existed in the cells of breast cancer. After it was found that ERs could be used as a predictive factor of endocrine therapy for breast cancer, the validity of endocrine therapy has became more certain. Tamoxifen, a major selective estrogen receptor modulator, is the first agent which has shown evidence of improving survival time and disease-free survival time in the treatment of breast cancer, and is the standard treatment, widely used in the treatment of breast cancer all over the world. LH-RH analogue, commonly used in ablation treatment among premenopausal women, produces the same effect as ovariectomy, and recently has shown good results equivalent to chemotherapy in premenopausal breast cancer treatment. Furthermore, aromatase inhibitors as a form of ablation treatment of postmenopausal women have been used recently. In comparison with tamoxifen, aromatase inhibitors have revealed the same or more effective result in postmenopausal breast cancer treatment. In the near future, endocrine mechanisms in the body and the molecular mechanisms of transcription by ER will be more clearly elucidated, and then new kinds of agent and combined therapies for the endocrine treatment of breast cancer will be developed. Currently, many clinical randomized trials are being conducted to examine the effectiveness of new endocrine treatment. Significant changes are occurring in the endocrine treatment of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0036635075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036635075&partnerID=8YFLogxK

M3 - Article

C2 - 12145993

AN - SCOPUS:0036635075

VL - 29

SP - 1138

EP - 1145

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 7

ER -